thiazolidines has been researched along with glucagon-like peptide 1 in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Beglinger, C; Drewe, J; Gutmann, H; Schlatter, P | 1 |
| Schwanstecher, C; Schwanstecher, M | 1 |
| Crajoinas, RO; Girardi, AC; Lessa, LM; Malnic, G; Oricchio, FT; Pacheco, BP; Pessoa, TD | 1 |
| Ogawa, D; Shikata, K | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Ahn, JH; Cha, BS; Choi, CS; Kang, ES; Kim, YW; Lee, BW; Lee, EY; Lee, HC; Oh, H | 1 |
| Hua, X; Kong, X; Ma, X; Mulder, H; Sun, J; Wu, X; Yan, D | 1 |
| Nakamura, S; Nakazato, M; Sakoda, H; Tsubouchi, C; Tsuchimochi, W; Ueno, H; Yamashita, E | 1 |
| Abiru, N; Ando, T; Fujishima, K; Haraguchi, A; Imaizumi, M; Kawakami, A; Matsumoto, K; Mori, F; Takamura, N; Yamasaki, H | 1 |
| Kubota, T; Moroi, M | 1 |
| Arakawa, K; Hikida, K; Ikenaga, Y; Kiuchi, S; Kuriyama, C; Matsushita, Y; Nakamaru, Y; Nakayama, K; Oguma, T; Oka, K; Saito, A; Shiotani, M; Ueta, K; Yoshida, K | 1 |
| Arakawa, K; Hikida, K; Kuriyama, C; Matsushita, Y; Minami, M; Nakayama, K; Oguma, T; Saito, A; Shiotani, M; Tsuda-Tsukimoto, M; Ueta, K | 1 |
| Bell, N; Caldwell, JS; Carreras, CW; Charmot, D; Chen, T; Finn, PD; He, L; Jacobs, JW; Kohler, J; Koo-McCoy, S; Kozuka, K; Lewis, JG; Navre, M; Reich, NW; Rodriguez, D; Spencer, AG; Tabora, J | 1 |
| Nie, G; Peng, W; Rao, D; Shi, Y; Wu, J; Xia, Q; Zhang, M | 1 |
| Hatware, K; Patil, K; Sharma, R; Sharma, S | 1 |
| Deguchi, H; Enzan, N; Ide, T; Ikeda, M; Ikeda, S; Ishikita, A; Matsushima, S; Okabe, K; Sada, M; Shinohara, K; Tadokoro, T; Tsutsui, H; Yamamoto, T | 1 |
3 review(s) available for thiazolidines and glucagon-like peptide 1
| Article | Year |
|---|---|
Targeting type 2 diabetes.
Topics: Adipose Tissue; Caloric Restriction; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Metformin; Signal Transduction; Thiazolidines | 2011 |
[Microinflammation in diabetic nephropathy].
Topics: Animals; Diabetic Nephropathies; Drug Design; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin Resistance; Metabolic Syndrome; Mice; Molecular Targeted Therapy; PPAR gamma; Rats; Thiazolidines | 2011 |
Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Half-Life; Humans; Pyrazoles; Thiazolidines | 2020 |
13 other study(ies) available for thiazolidines and glucagon-like peptide 1
| Article | Year |
|---|---|
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cells, Cultured; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Immunohistochemistry; Kidney Tubules, Proximal; Kinetics; Pentanoic Acids; Peptides; Receptors, Glucagon; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Swine; Thiazolidines; Venoms | 2007 |
Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
Topics: Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Kidney; Natriuretic Agents; Pentanoic Acids; Peptides; Phosphorylation; Rats; Rats, Wistar; Receptors, Glucagon; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Thiazolidines; Venoms | 2011 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Diabetes Mellitus; Diet, High-Fat; Dipeptidyl Peptidase 4; Eating; Energy Metabolism; Enzyme Inhibitors; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Random Allocation; Thiazolidines; Treatment Outcome; Valine; Weight Gain | 2014 |
Glucagon-like peptide 1 stimulates insulin secretion via inhibiting RhoA/ROCK signaling and disassembling glucotoxicity-induced stress fibers.
Topics: Actins; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cytochalasin B; Female; Glucagon-Like Peptide 1; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice, Inbred C57BL; Rats; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Stress Fibers; Thiazolidines | 2014 |
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Topics: Aged; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Japan; Middle Aged; Monitoring, Ambulatory; Postprandial Period; Pyrazoles; Thiazolidines | 2015 |
Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
Topics: Adult; Aged; Alanine Transaminase; Anthropometry; Biguanides; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Male; Middle Aged; Peptides; Prognosis; Retrospective Studies; Sulfonylurea Compounds; Thiazolidines; Treatment Outcome; Venoms | 2014 |
Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.
Topics: Animals; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Diuretics; Glucagon-Like Peptide 1; Male; Natriuresis; Natriuretic Agents; Pyrazoles; Rats; Rats, Wistar; Thiazolidines | 2015 |
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Topics: Administration, Oral; Animals; Canagliflozin; Cells, Cultured; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Pyrazoles; Rats, Zucker; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2015 |
Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Topics: Animals; Canagliflozin; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Monosaccharides; Pyrazoles; Pyridines; Rats; Rats, Inbred F344; Sitagliptin Phosphate; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2016 |
Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
Topics: Animals; Dogs; Drug Design; Drug Evaluation, Preclinical; Female; Gallbladder; Gastrointestinal Agents; Glucagon-Like Peptide 1; HEK293 Cells; Humans; Madin Darby Canine Kidney Cells; Male; Mice, Inbred C57BL; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Thiazolidines | 2018 |
Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Cell Line; Cell Survival; Chemokine CCL2; Dipeptidyl Peptidase 4; Doxorubicin; Glucagon-Like Peptide 1; Humans; Inflammation; Insulin Resistance; Interleukin-1beta; Myocytes, Cardiac; Oxidative Stress; Pyrazoles; Rats; Reactive Oxygen Species; Receptors, KIR3DL1; Thiazolidines | 2020 |
DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathw
Topics: Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Rate; Histone Deacetylases; Mice; Myocytes, Cardiac; NADPH Oxidase 4; Oxidative Stress; Pyrazoles; Rats; Signal Transduction; Thiazolidines | 2020 |